Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Glaxosmithkline Research & Development Limited, AstraZeneca AB

Conditions

Esophageal Cancer Expressing Claudin18.2Gastric CancerGastroesophageal Junction AdenocarcinomaMMRp/ MSS colon cancer

Phase 2

A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 or Stage III MMRp/ MSS colon cancer

RecruitingCTIS2024-513441-36-00

Glaxosmithkline Research & Development LimitedMMRp/ MSS colon cancer

Start: 2024-11-27Target: 170Updated: 2025-12-18

Phase 3

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Not yet recruitingCTIS2024-519787-40-00

AstraZeneca ABEsophageal Cancer Expressing Claudin18.2, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Target: 126Updated: 2026-06-17